Cargando…

Hypercalcemia of Malignancy and Colorectal Cancer

Our aim is to describe the association between colorectal cancer (CRC) and humoral hypercalcemia of malignancy (HHM). Causes of hypercalcemia of malignancy include parathyroid hormone-related peptide (PTHrP) secretion, local osteolysis, calcitriol production and ectopic parathyroid hormone (PTH) sec...

Descripción completa

Detalles Bibliográficos
Autores principales: Galindo, Rodolfo J., Romao, Isabela, Valsamis, Ageliki, Weinerman, Stuart, Harris, Yael Tobi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4797652/
https://www.ncbi.nlm.nih.gov/pubmed/26998187
http://dx.doi.org/10.14740/wjon953w
_version_ 1782421997147389952
author Galindo, Rodolfo J.
Romao, Isabela
Valsamis, Ageliki
Weinerman, Stuart
Harris, Yael Tobi
author_facet Galindo, Rodolfo J.
Romao, Isabela
Valsamis, Ageliki
Weinerman, Stuart
Harris, Yael Tobi
author_sort Galindo, Rodolfo J.
collection PubMed
description Our aim is to describe the association between colorectal cancer (CRC) and humoral hypercalcemia of malignancy (HHM). Causes of hypercalcemia of malignancy include parathyroid hormone-related peptide (PTHrP) secretion, local osteolysis, calcitriol production and ectopic parathyroid hormone (PTH) secretion. Hypercalcemia of malignancy in patients with CRCs is a rare scenario. A patient with anal squamous cell carcinoma was admitted with hypercalcemia, suppressed PTH and hypophosphatemia. He was found to have metastatic anal squamous cell carcinoma to the liver. Further evaluation revealed elevated PTHrP and 1,25-dihydroxyvitamin D and low 25-hydroxyvitamin D. Over a 5-month course, the hypercalcemia responded poorly to bisphosphonates, transiently to prednisone, but showed marked improvement with chemotherapy. A review of English language publications in Pubmed and a reference search of retrieved articles revealed 29 cases of CRC causing PTHrP-mediated hypercalcemia. Most patients were middle-aged men (mean ± SD: 56.7 ± 13.4 years), with advanced metastatic cancer (85% with hepatic metastasis) and severe hypercalcemia (mean ± SD: 15.6 ± 1.9 mg/dL, 62% with Ca > 14). This condition is associated with high mortality (79%) and short survival (median 54.5 days, CI: 21 - 168). Despite being uncommon, HHM (PTHrP-mediated) should be considered in patients with metastatic CRC presenting with hypercalcemia. Clinicians should be aware that combined etiologies may be present, particularly in cases of resistant hypercalcemia. Treatment of the underlying malignancy is essential for calcium control.
format Online
Article
Text
id pubmed-4797652
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Elmer Press
record_format MEDLINE/PubMed
spelling pubmed-47976522016-03-18 Hypercalcemia of Malignancy and Colorectal Cancer Galindo, Rodolfo J. Romao, Isabela Valsamis, Ageliki Weinerman, Stuart Harris, Yael Tobi World J Oncol Case Report Our aim is to describe the association between colorectal cancer (CRC) and humoral hypercalcemia of malignancy (HHM). Causes of hypercalcemia of malignancy include parathyroid hormone-related peptide (PTHrP) secretion, local osteolysis, calcitriol production and ectopic parathyroid hormone (PTH) secretion. Hypercalcemia of malignancy in patients with CRCs is a rare scenario. A patient with anal squamous cell carcinoma was admitted with hypercalcemia, suppressed PTH and hypophosphatemia. He was found to have metastatic anal squamous cell carcinoma to the liver. Further evaluation revealed elevated PTHrP and 1,25-dihydroxyvitamin D and low 25-hydroxyvitamin D. Over a 5-month course, the hypercalcemia responded poorly to bisphosphonates, transiently to prednisone, but showed marked improvement with chemotherapy. A review of English language publications in Pubmed and a reference search of retrieved articles revealed 29 cases of CRC causing PTHrP-mediated hypercalcemia. Most patients were middle-aged men (mean ± SD: 56.7 ± 13.4 years), with advanced metastatic cancer (85% with hepatic metastasis) and severe hypercalcemia (mean ± SD: 15.6 ± 1.9 mg/dL, 62% with Ca > 14). This condition is associated with high mortality (79%) and short survival (median 54.5 days, CI: 21 - 168). Despite being uncommon, HHM (PTHrP-mediated) should be considered in patients with metastatic CRC presenting with hypercalcemia. Clinicians should be aware that combined etiologies may be present, particularly in cases of resistant hypercalcemia. Treatment of the underlying malignancy is essential for calcium control. Elmer Press 2016-02 2016-04-03 /pmc/articles/PMC4797652/ /pubmed/26998187 http://dx.doi.org/10.14740/wjon953w Text en Copyright 2016, Galindo et al. http://creativecommons.org/licenses/by/2.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Galindo, Rodolfo J.
Romao, Isabela
Valsamis, Ageliki
Weinerman, Stuart
Harris, Yael Tobi
Hypercalcemia of Malignancy and Colorectal Cancer
title Hypercalcemia of Malignancy and Colorectal Cancer
title_full Hypercalcemia of Malignancy and Colorectal Cancer
title_fullStr Hypercalcemia of Malignancy and Colorectal Cancer
title_full_unstemmed Hypercalcemia of Malignancy and Colorectal Cancer
title_short Hypercalcemia of Malignancy and Colorectal Cancer
title_sort hypercalcemia of malignancy and colorectal cancer
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4797652/
https://www.ncbi.nlm.nih.gov/pubmed/26998187
http://dx.doi.org/10.14740/wjon953w
work_keys_str_mv AT galindorodolfoj hypercalcemiaofmalignancyandcolorectalcancer
AT romaoisabela hypercalcemiaofmalignancyandcolorectalcancer
AT valsamisageliki hypercalcemiaofmalignancyandcolorectalcancer
AT weinermanstuart hypercalcemiaofmalignancyandcolorectalcancer
AT harrisyaeltobi hypercalcemiaofmalignancyandcolorectalcancer